Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2017

View Archived Issues

GeoVax's GEO-ZM02 provides 100% protection to mice infected with lethal dose of Zika virus

X-Chem announces strategic collaboration with Astellas Pharma

Phase III SUMMIT-07 study of NKTR-181 meets endpoints

FDA grants orphan drug designation to NantKwest's activated natural killer cell therapy

SMARt-420 reverses ethionamide-acquired resistance in Mycobacterium tuberculosis

Pierre Fabre and H-Immune establish research partnership in cancer immunotherapy

New phase I/II trial explores use of APX-005M with pembrolizumab in metastatic melanoma

EMA gives positive scientific advice on approval pathway for Actinium's Iomab-B

Heat Biologics reports phase II interim data on HS-110 with nivolumab in NSCLC

Nemus Bioscience and Nanomerics sign agreement to advance ocular formulation of NB-1111

First-in-human study for Actelion's insomnia candidate ACT-541468 completed

FDA approves Xadago for Parkinson's disease

CTD begins recruitment for European phase I/II trial of Trappsol Cyclo in NPC

Novartis' phase III RELAX-AHF-2 study of RLX-030 does not meet primary endpoints

L-theanine shows promise for treating asthma

Protein Sciences announces BARDA request for new H7N9 pandemic vaccine candidates

Upside Biotechnologies raises Series A funds to advance skin replacement therapy for burns

Healthy subjects receive JNJ-63823539, a new TNF-alpha and IL-17A bispecific antibody

Arix Bioscience signs collaboration agreements to develop therapeutics for metabolic diseases

Melatonin oral gel developed as prophylactic treatment for oral mucositis after radiotherapy

Alla Chem patents hepatitis C virus NS5A inhibitors

Bristol-Myers Squibb describes novel TGF-beta receptor antagonists

Takeda presents new toll-like receptor inhibitors

The University of Arizona divulges novel DYRK1A inhibitors

Lysosomal Therapeutics discovers novel glucosylceramidase activators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...